Literature DB >> 23643389

Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.

Yujun Hao1, Chao Wang, Bo Cao, Brett M Hirsch, Jing Song, Sanford D Markowitz, Rob M Ewing, David Sedwick, Lili Liu, Weiping Zheng, Zhenghe Wang.   

Abstract

PIK3CA, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase α, is frequently mutated in human cancers. Most of these mutations occur at two hot-spots: E545K and H1047R located in the helical domain and the kinase domain, respectively. Here, we report that p110α E545K, but not p110α H1047R, gains the ability to associate with IRS1 independent of the p85 regulatory subunit, thereby rewiring this oncogenic signaling pathway. Disruption of the IRS1-p110α E545K interaction destabilizes the p110α protein, reduces AKT phosphorylation, and slows xenograft tumor growth of a cancer cell line expressing p110α E545K. Moreover, a hydrocarbon-stapled peptide that disrupts this interaction inhibits the growth of tumors expressing p110α E545K.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23643389      PMCID: PMC3671608          DOI: 10.1016/j.ccr.2013.03.021

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  33 in total

Review 1.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

2.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

3.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hae Woo Lee; Won Sang Park; Suk Woo Nam; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

4.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  The PIK3CA gene is mutated with high frequency in human breast cancers.

Authors:  Kurtis E Bachman; Pedram Argani; Yardena Samuels; Natalie Silliman; Janine Ptak; Steve Szabo; Hiroyuki Konishi; Bedri Karakas; Brian G Blair; Clarence Lin; Brock A Peters; Victor E Velculescu; Ben Ho Park
Journal:  Cancer Biol Ther       Date:  2004-08-26       Impact factor: 4.742

6.  Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.

Authors:  Loren D Walensky; Andrew L Kung; Iris Escher; Thomas J Malia; Scott Barbuto; Renee D Wright; Gerhard Wagner; Gregory L Verdine; Stanley J Korsmeyer
Journal:  Science       Date:  2004-09-03       Impact factor: 47.728

7.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.

Authors:  Chuan-Hsiang Huang; Diana Mandelker; Oleg Schmidt-Kittler; Yardena Samuels; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Sandra B Gabelli; L Mario Amzel
Journal:  Science       Date:  2007-12-14       Impact factor: 47.728

8.  Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.

Authors:  Daniel K Broderick; Chunhui Di; Timothy J Parrett; Yardena R Samuels; Jordan M Cummins; Roger E McLendon; Daniel W Fults; Victor E Velculescu; Darell D Bigner; Hai Yan
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma.

Authors:  M E Pacold; S Suire; O Perisic; S Lara-Gonzalez; C T Davis; E H Walker; P T Hawkins; L Stephens; J F Eccleston; R L Williams
Journal:  Cell       Date:  2000-12-08       Impact factor: 41.582

10.  Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).

Authors:  John E Burke; Olga Perisic; Glenn R Masson; Oscar Vadas; Roger L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

View more
  45 in total

1.  A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.

Authors:  Brian G Blair; Xinyan Wu; Muhammad Saddiq Zahari; Morassa Mohseni; Justin Cidado; Hong Yuen Wong; Julia A Beaver; Rory L Cochran; Daniel J Zabransky; Sarah Croessmann; David Chu; Patricia Valda Toro; Karen Cravero; Akhilesh Pandey; Ben Ho Park
Journal:  Proteomics       Date:  2014-12-28       Impact factor: 3.984

2.  PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.

Authors:  Sarah Croessmann; Hong Yuen Wong; Daniel J Zabransky; David Chu; D Marc Rosen; Justin Cidado; Rory L Cochran; W Brian Dalton; Bracha Erlanger; Karen Cravero; Berry Button; Kelly Kyker-Snowman; Paula J Hurley; Josh Lauring; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2017-02-11       Impact factor: 4.872

Review 3.  Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.

Authors:  Yujun Hao; Shuliang Zhao; Zhenghe Wang
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

Review 4.  An enhanced functional interrogation/manipulation of intracellular signaling pathways with the peptide 'stapling' technology.

Authors:  Y He; D Chen; W Zheng
Journal:  Oncogene       Date:  2015-03-23       Impact factor: 9.867

Review 5.  Targeting kinase signaling pathways with constrained peptide scaffolds.

Authors:  Laura E Hanold; Melody D Fulton; Eileen J Kennedy
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

6.  Novel all-hydrocarbon stapled p110α[E545K] peptides as blockers of the oncogenic p110α[E545K]-IRS1 interaction.

Authors:  Xiao Hu; Yanhua He; Liping Wu; Yujun Hao; Zhenghe Wang; Weiping Zheng
Journal:  Bioorg Med Chem Lett       Date:  2017-11-12       Impact factor: 2.823

Review 7.  PI3K: A Crucial Piece in the RAS Signaling Puzzle.

Authors:  Agata Adelajda Krygowska; Esther Castellano
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

8.  Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.

Authors:  Shanthi Kanthala; Sashikanth Banappagari; Ameya Gokhale; Yong-Yu Liu; Gu Xin; Yunfeng Zhao; Seetharama Jois
Journal:  Chem Biol Drug Des       Date:  2014-11-06       Impact factor: 2.817

9.  Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor.

Authors:  Hyang Sook Seol; Hyo Jeong Kang; Hyojeong Kang; Seul-I Lee; Na Eun Kim; Tae Im Kim; Sung Min Chun; Tae Won Kim; Chang Sik Yu; Young-Ah Suh; Shree Ram Singh; Suhwan Chang; Se Jin Jang
Journal:  Cancer Lett       Date:  2013-12-11       Impact factor: 8.679

Review 10.  How do oncoprotein mutations rewire protein-protein interaction networks?

Authors:  Emily H Bowler; Zhenghe Wang; Rob M Ewing
Journal:  Expert Rev Proteomics       Date:  2015-09-01       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.